Home News PMPRB

07

Mar2023

Mélanie Bourassa Forcier References “Dialogue of the Deaf” Between PMPRB and Industry Among Reasons for her Resignation from PMPRB

In the wake of media attention around recent high-profile resignations from PMPRB, Melanie Bourassa Forcier, former Acting Chairperson of the PMPRB who resigned in December, came forward to "rectify the facts” about her reasons for resigning this past weekend.In her 5-page letter dated March 3rd and published on ... Read More

24

Feb2023

Doug Clark Resigns from PMPRB

On February 24, 2023, Doug Clark announced he is stepping down from his position as Executive Director of the PMPRB after almost a decade with PMPRB. Clark will continue to serve as a special advisor to the Board as he transitions to retirement from the federal public service. ... Read More

24

Feb2023

PMPRB Board Member Resigns

On February 23, 2023, Matthew Herder, a PMPRB Board Member since 2018, publicly announced his resignation from the PMPRB. He shared his resignation letter on his personal twitter page today. The letter, which he notes was submitted to Health Minister Jean-Yves Duclos on Monday, outlines his reasons for parting ways with ... Read More

13

Feb2023

PMPRB New Chairperson

On Wednesday, February 1, 2023, the Minister of Health announced the appointment of Thomas J Digby as the new Chairperson for the PMPRB. This nomination comes after over a year of being vacant when Dr. Mitchell Levine completed his five-year term tenure on November 2021. Thomas J. Digby ... Read More

19

Dec2022

PMPRB Interim Chairperson Confirms Resignation

Mélanie Bourassa Forcier, Vice-Chairperson and Acting Chairperson of the Patented Medicine Prices Review Board (PMPRB), confirmed her resignation from the Board on Twitter on December 7, 2022. In her comment she indicated she is evaluating her legal obligations concerning whether she can share the reasons for her ... Read More

05

Dec2022

PMPRB’s 2021 Annual Report Shows Worrying Decline in Number of New Medicines Launched in Canada; HDAP Meeting Tentatively Scheduled for Spring 2023

Last week the Patented Medicine Prices Review Board (PMPRB) presented its 2021 Annual Report  to Federal Health Minister Duclos in accordance with its reporting mandate outlined in sections 89 and 100 of the Patent Act. Key statistics reinforce concerns about Canada’s continued attractiveness for new medicine launch ... Read More

22

Nov2022

PDCI Launches Sharing Page for PMRPB Consultation on Draft Guidelines- Fall 2022

On October 6, 2022, the Patented Medicine Prices Review Board (PMPRB) published its Draft price regulatory Guidelines and has invited stakeholders to comment on its approach by December 5, 2022. PDCI strives to support timely transparency around public policy consultations and invites organizations and individuals who provided comments to ... Read More

13

Oct2022

PDCI’s Early Insights on PMPRB Draft Guidelines

On October 6, 2022, the Patented Medicine Prices Review Board (PMPRB) published its highly anticipated draft price regulatory Guidelines and has invited stakeholders to comment on its approach by December 5, 2022.While some aspects of these guidelines were anticipated, there are a number of new concerns and uncertainties ... Read More

06

Oct2022

PMPRB Releases Draft Guidelines and Launches 60-day consultation 

The Patented Medicine Prices Review Board (PMPRB) today, Ocober 6, 2022, released its draft PMPRB Guidelines with a 60-day consultation period running until December 5, 2022. PMPRB maintains that final Guidelines will be issued by end of this year and previously indicated its intent for new Guidelines ... Read More

19

Aug2022

PMPRB Implements its Interim Guidelines with Clarifications

On August 18, 2022, PMPRB announced its decisions regarding Price Regulation of patented medicines during the ‘Interim Period’, between July 1, 2022 and when a final set of price regulatory guidelines is published. The PMPRB has decided to move forward with earlier proposals drafted June 30th, 2022, and ... Read More